Back to Journals » Biologics: Targets and Therapy » Volume 14

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease

Authors Al Sulais E, AlAmeel T

Received 29 October 2019

Accepted for publication 19 December 2019

Published 10 January 2020 Volume 2020:14 Pages 1—11

DOI https://doi.org/10.2147/BTT.S236433

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Doris Benbrook


Eman Al Sulais, 1 Turki AlAmeel 2

1Department of Medicine, Royal Commission Hospital, Jubail, Saudi Arabia; 2Department of Medicine, King Fahad Specialist Hospital, Dammam, Saudi Arabia

Correspondence: Eman Al Sulais
Department of Medicine, Royal Commission Hospital, P.O. Box 496, Jubail, Qatif 31911, Saudi Arabia
Email e.alslais@gmail.com

Abstract: Anti- tumor Necrosis Factor (anti-TNF) agents are the backbone treatment of moderate to severe cases of inflammatory bowel disease. One of the main drawbacks of these agents is the high cost. The introduction of biosimilar products to anti-TNF agents is expected to lower the cost. Health care providers ought to be aware of the available data that addresses the safety and efficacy of biosimilars in IBD patients. This article outlines the current evidence-based data regarding the available biosimilar products, their safety, efficacy and how to deal with patients’ concerns.

Keywords: biosimilars, inflammatory bowel disease, tumor necrosis factor inhibitors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]